Evusheld: first product approved for pre-exposure prophylaxis of COVID-19Tixagevimab and cilgavimab are long-acting monoclonal antibodies given by intramuscular injection. Updated edition of the Canadian Tuberculosis Standards is now availableProvides practical information on all aspects of tuberculosis (TB) in Canada, including epidemiology, transmission, diagnosis and management. Aspirin beneficial to hospitalized COVID-19 patients Even though many getting Aspirin were more likely to have other risk factors. Pfizer COVID-19 vaccine 'grey-cap' vials that do not require dilution coming soon Health Canada has approved an alternative to the original Pfizer COVID-19 vaccine “purple-cap” vials, for individuals 12 years of age or older. An overview of Covifenz: The first plant-based COVID-19 vaccine approved in Canada NACI suggests that, like Nuvaxovid, Covifenz may be an option for people unable or unwilling to receive an mRNA COVID-19 vaccine. Patients worried about COVID risk and travel? CATMAT issues guidance statement Travel may increase the risk of COVID-19, even while following recommended precautions. Effectiveness of COVID-19 vaccines and booster dose against the Omicron variant Study examines effectiveness after two doses of Pfizer, AstraZeneca or Moderna vaccine and after a booster dose with Pfizer, AstraZeneca or Moderna vaccine. Single-dose Janssen COVID-19 vaccine less effective than two-dose Pfizer vaccine French study compares effectiveness of Janssen vaccine versus Pfizer vaccine against COVID-19–related hospitalization. Health Canada considering Evusheld for COVID-19 pre-exposure prophylaxis Single doses of tixagevimab and cilgavimab reduce incidence of symptomatic COVID-19 in at-risk adults for a six-month period. Vaccines against Sars-CoV-2 lose effectiveness in preventing infection after several months But they still offer strong protection in preventing severe disease. First Previous 22 23 24 25 26 Next Last
